🇺🇸 FDA
Company

NEUROCRINE

NEUROCRINE BIOSCIENCES INC

NBIX biotech USA

Quick answer

NEUROCRINE is a biotech company (NBIX) headquartered in SAN DIEGO, CA, USA with 24 tracked pipeline programs.

Pipeline (24)

project

Chronocort®

Congenital Adrenal Hyperplasia

Phase 3 · small_molecule · completed

5 trials project

Crinecerfont

Congenital Adrenal Hyperplasia

Phase 3 · small_molecule · active

4 trials project

Hydrocortisone

Congenital Adrenal Hyperplasia

Phase 3 · small_molecule · completed

2 trials project

Indiplon

Insomnia

Phase 3 · small_molecule · terminated

1 trials project

Infacort®

Adrenal Insufficiency

Phase 3 · small_molecule · completed

4 trials project

NBI-1065845

Major Depressive Disorder

Phase 3 · small_molecule · active

5 trials project

NBI-1117568

Schizophrenia

Phase 3 · small_molecule · active

5 trials project

NBI-34060

Insomnia

Phase 3 · small_molecule · terminated

1 trials project

NBI-98854

Tardive Dyskinesia

Phase 3 · small_molecule · completed

6 trials project

Placebo

Schizophrenia

Phase 3 · small_molecule · completed

2 trials project

Placebo

Dyskinesia

Phase 3 · small_molecule · completed

1 trials project

Valbenazine

Tardive Dyskinesia

Phase 3 · small_molecule · completed

2 trials project

Valbenazine

Chorea, Huntington

Phase 3 · small_molecule · active

3 trials project

Chronocort

Primary Adrenal Insufficiency

Phase 2 · small_molecule · completed

1 trials project

Crinecerfont

CAH - Congenital Adrenal Hyperplasia

Phase 2 · small_molecule · completed

1 trials project

Hydrocortisone Modified Release Capsules

Endocrine Disease

Phase 2 · small_molecule · completed

1 trials project

Luvadaxistat

Schizophrenia

Phase 2 · small_molecule · completed

2 trials project

NBI-1065890

Tardive Dyskinesia

Phase 2 · small_molecule · active

1 trials project

NBI-1070770

Major Depressive Disorder

Phase 2 · small_molecule · completed

1 trials project

NBI-1117568

Bipolar I Disorder

Phase 2 · small_molecule · active

1 trials project

NBI-1117570

Schizophrenia

Phase 2 · small_molecule · active

1 trials project

NBI-5788

Multiple Sclerosis

Phase 2 · small_molecule · completed

1 trials project

NBI-74788

CAH - Congenital Adrenal Hyperplasia

Phase 2 · small_molecule · completed

1 trials project

NBI-827104

Epileptic Encephalopathy

Phase 2 · small_molecule · terminated

2 trials

Drugs (2)

drug

crinecerfont

CRENESSITY

 drug

valbenazine tosylate

VALBENAZINE TOSYLATE

Patents (8)

patent

US 12421193

GPR52 modulators and methods of use

Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12383536

CRF receptor antagonists and methods of use

Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12128033

Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1

Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12102637

Pharmaceutical formulations for treating endometriosis, uterine fibroids, polycy

Expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12083227

Solid pharmaceutical formulations for treating endometriosis, uterine fibroids,

Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11730739

Treatment of congenital adrenal hyperplasia

Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11718618

Substituted pyrido[2,1-a]isoquinolines as VMAT2 inhibitors

Expires Mon Aug 03 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11713324

Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

Expires Mon Jul 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)